Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
This antibody is predicted to react with rat based on sequence homology.
Suggested positive control: Hela whole cell extract.
CYLD is a 956 aa, cytoplasmic, deubiquitinating enzyme belonging to the ubiquitin carboxy-terminal hydrolases (UCH) family of proteins with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains, a proline rich region, a SH3 binding domain and a sequence homology to catalytic domain of UCH. CYLD is identified as a tumor suppressor protein affecting the JNK signaling pathway. CYLD is a negative regulator of TRAF2 and NF-kappa-B signaling pathway and is also known to have receptor-dependent role in regulating the I-kappa-B kinase pathway. It also has a deubiquitinating activity that is directed towards non-Lys-48-linked polyubiquitin chains and TRAP1 is a novel substrate for deubiquitination. Mutated CYLD is known to be associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: cylindromatosis (turban tumor syndrome); Deubiquitinating enzyme CYLD; FLJ20180; FLJ31664; FLJ78684; probable ubiquitin carboxyl-terminal hydrolase CYLD; Ubiquitin carboxyl-terminal hydrolase CYLD; ubiquitin specific peptidase like 2; Ubiquitin thioesterase CYLD; ubiquitin thiolesterase CYLD; Ubiquitin-specific-processing protease CYLD
Gene Aliases: BRSS; CDMT; CYLD; CYLD1; CYLDI; EAC; HSPC057; KIAA0849; MFT; MFT1; SBS; TEM; USPL2
UniProt ID: (Human) Q9NQC7
Entrez Gene ID: (Human) 1540
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn moreGet expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support